Tarsus_Logo_Parnership_Announcement.jpg
Tarsus Pharmaceuticals, Inc. to Present at the BofA Securities 2021 Virtual Health Care Conference
27 avr. 2021 16h05 HE | Tarsus Pharmaceuticals, Inc
IRVINE, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply...
Tarsus_Logo_Parnership_Announcement.jpg
Tarsus Pharmaceuticals, Inc. Reports Full-Year 2020 Financial Results and Business and Clinical Updates
31 mars 2021 16h05 HE | Tarsus Pharmaceuticals, Inc
Enrollment complete for Saturn-1, first TP-03 pivotal trial for the treatment of Demodex blepharitis; initiation of Saturn-2 expected in Q2 2021 Strategic partnership with LianBio in March 2021 for...
Tarsus_Logo_Parnership_Announcement.jpg
Tarsus Pharmaceuticals and LianBio Announce Strategic Partnership to Develop and Commercialize TP-03 in Greater China for the Treatment of Demodex Blepharitis and Meibomian Gland Disease
29 mars 2021 16h05 HE | Tarsus Pharmaceuticals, Inc
IRVINE, Calif., SHANGHAI, China and PRINCETON, N.J., March 29, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company, and LianBio, a...
Tarsus_Logo_Parnership_Announcement.jpg
Tarsus Pharmaceuticals与联拓生物宣布建立战略合作,携手在大中华区对用于治疗蠕形螨睑缘炎和睑板腺功能障碍的TP-03进行开发和商业化
29 mars 2021 16h05 HE | Tarsus Pharmaceuticals, Inc
尔湾(加利福尼), 上海和普林斯顿(新泽西), March 30, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals(纳斯达克交易代码:...
Bryan Wahl MD JD_General Counsel_Tarsus
Tarsus Pharmaceuticals, Inc. Appoints Bryan Wahl, MD, JD as General Counsel
19 janv. 2021 08h30 HE | Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough...
Dianne Whitfield2
Tarsus Pharmaceuticals, Inc. Appoints Dianne Whitfield as Chief Human Resources Officer
07 janv. 2021 09h24 HE | Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough...
Tarsus Logo.png
Tarsus Pharmaceuticals, Inc. to Present at the 2021 ICR Virtual Conference
05 janv. 2021 17h00 HE | Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough...
Tarsus Logo.png
Tarsus Pharmaceuticals, Inc. Announces Type C Meeting with FDA Regarding NDA Submission Requirements for Lead Candidate TP-03
23 déc. 2020 07h00 HE | Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough...
Tarsus Logo.png
Tarsus Pharmaceuticals, Inc. Announces Inclusion in the Russell 3000® Index and Russell 2000® Index
21 déc. 2020 07h00 HE | Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough...
Tarsus Logo.png
Tarsus Pharmaceuticals, Inc. Appoints Wendy Yarno to Board of Directors
19 nov. 2020 15h24 HE | Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough...